Key Drivers
- High gross margin
- Solid cash generation
- Leverage & spend
AIAI Summary
Exact Sciences has shifted from a pure MCED growth story to a hybrid cash‑flow and deal‑driven investment where sustained sequential EBITDA/margin conversion (via the $150M productivity program) or a clean Abbott transaction/litigation outcome will likely unlock value, while reimbursement delays, PTAB/IP rulings and high leverage are the principal downside risks to watch.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Solid cash generation
- •Leverage & spend
EXAS combines strong gross margins and solid free cash flow supporting liquidity, but persistent net losses, heavy R&D/SG&A that flipped recent EBITDA negative, and significant leverage alongside rich valuation create meaningful downside risk.
Price Behavior
Key Price Behavior Insights:
- •Above short MA
- •Tight low volatility
- •Near‑term cap
EXAS is trading just above its short moving average after a very tight, low‑volatility range last month, with immediate support near $103.20 and near‑term resistance at the $104.91 high, implying only mild upside without a catalyst.
Very low day‑to‑day volatility and a narrow trading range over the last month
Sentiment & News
Key News Insights:
- •Institutional buying
- •New clinical data
- •Screening partnerships
Exact Sciences drew notable institutional accumulation, advancing clinical data and screening partnerships while earning workplace recognition, with no indications of regulatory or executive setbacks.
Continued investor buying combined with fresh MRD/multi-cancer data and strong commercial partnerships should support positive sentiment and potential re-rating absent regulatory or leadership concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings